# BridgeBio Oncology Therapeutics Inc. Common Stock (BBOT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.98, market value $720 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). BridgeBio Oncology Therapeutics Inc. Common Stock reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.2×**. The shares trade at 2.2× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -32.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 99.9%**. Earnings per share rose 99.9%.

## Financial health
- **Current ratio: 12.34** (quick 12.34). Current assets cover the next year's liabilities 12.34 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. BridgeBio Oncology Therapeutics Inc. Common Stock does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover BridgeBio Oncology Therapeutics Inc. Common Stock; the consensus is strong_buy, with an average price target of $24.90 (+177% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -10.9%** (YTD -28.3%, 3-mo 15.0%). The shares are down 10.9% over twelve months including dividends.
- **From 52-week high: -39.6%** (28.3% above the low). Trading 40% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 1.36** (volatility 64%). Beta of 1.36 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BBOT · Page: https://foliofundamentals.com/stocks/bbot

Not investment advice.